CD8A and neoplasm: The tumor-promoting activity of this metabolite was reported by recent studies: Zhao et al. (Zhao et al., 2022) reported that intracellular itaconate was higher in polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs) than naïve bone marrow cells, and they proposed a non-cell-autonomous mechanism where itaconate produced by myeloid cells is secreted out, up-taken by T cells, and then attenuates CD8+ T cell proliferation and function.